Our sister site, Drug Delivery Business News, reports today that the Westfield, Indiana-based company can now begin a Phase 1 study to evaluate its proprietary, temperature-stable insulin. It aims to deliver a functional cure for type 1 diabetes.
Currently, externally-worn insulin pumps like Insulet’s Omnipod 5, Medtronic’s MiniMed 780G, Tandem Diabetes Care’s t:slim X2 and Mobi and Beta Bionics’ iLet lead the way. These devices utilize closed-loop capabilities, although they have programmable and hybrid settings to manage insulin delivery. Insulet has a fully closed-loop system under development, while iLet aims to serve as a closed-loop “bionic pancreas” as well.
An implantable system from Portal Diabetes would mark a first on the U.S. market.
Get the full story at our sister site, Drug Delivery Business News.
